DOCSLIB.ORG

WCLC 2020 English

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WCLC 2020 English © Springer-Verlag 2021 www.memoinoncology.com www.memoinoncology.com 01/21 memo – inOncology SPECIAL ISSUE Congress Report WCLC 2020 A GLOBAL CONGRESS DIGEST ON LUNG CANCER Report from the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer, 28th–31st January 2021, virtual congress IMPRESSUM/PUBLISHER Media owner and publisher: Springer-Verlag GmbH, AT, Prinz-Eugen-Straße 8–10, 1040 Vienna, Austria, Tel.: +43/(0)1/330 24 15-0, Fax: +43/(0)1/330 24 26, Internet: www.springer.at, www.SpringerMedizin.at. Owner and Copyright: © 2021 Springer-Verlag GmbH Austria, part of Springer Nature. Managing Directors: Joachim Krieger, Juliane Ritt, Dr. Alois Sillaber. Medical Writer: Dr. Judith Moser. Corporate Publishing: Elise Haidenthaller. Editorial Support: Anna Fenzl, PhD. Layout: Katharina Bruckner. Published in Vienna. Produced in Linz. Printer: Global-Print, Wien, Austria. The editors of “memo, magazine of european medical oncology” assume no responsibility for this supplement. The Publisher does not assume any legal liability or responsibility for the accuracy, completeness, or usefulness of the information supplied herein, nor for any opinion expressed. The Publisher, its agent, and employees will not be liable for any loss or damage arising directly or indirectly from possession, publication, use of, or reliance on information obtained from this report. It is provided in good faith without express of implied warranty. Reference to any specific commercial product or service does not imply endorsement or recommendation by the Publisher. All articles are peer-reviewed and protected from any commercial influence. This issue is intended only for healthcare professionals outside the US, the UK and Australia. WCLC 2020 special issue Table of Contents 3 Preface 3 Pushing the bounds in early-stage lung cancer 8 KRAS, HER2 & ALK: targeted options and sequencing issues 11 Specific treatment approaches in the EGFR-mutated setting 15 Interview: Antibody-drug conjugates: the age of almost unlimited possibilities has just begun 16 What is new in SCLC? 18 Immunotherapy: combination regimens and new data on the significance of mutations 21 Interview: Lung cancer screening: hurdles in daily routine and in the research laboratory 22 Nivolumab as a new option in patients with relapsed malignant mesothelioma 23 J-AXEL: nab-paclitaxel at least equal to docetaxel in pretreated NSCLC © metamorworks / Getty Images iStock Editorial Board: Alex A. Adjei, MD, PhD, Mayo Clinic, Department of Oncology, Rochester, Minnesota, USA Maria Rosario Garcia Campelo, MD, Lung Cancer and Thoracic Tumors, University Hospital Quirón A Coruña, La Coruña, Spain Federico Cappuzzo, MD, Medical Oncology Department, Ospedale Civile di Livorno, Livorno, Italy Wolfgang Hilbe, MD, Departement of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria Vera Hirsh, MD, McGill University, Health Centre, Montreal, Quebec, Canada Maximilian Hochmair, MD, Department of Respiratory and Critical Care Medicine, KH Nord, Vienna, Austria Herbert H F Loong, MD, The Chinese University of Hong Kong, Department of Clinical Oncology, Hong Kong Massimo Di Maio, MD, National Institute of Tumor Research and Therapy, Foundation G. Pascale, Napoli, Italy Filippo de Marinis, MD, PhD, Director of the Thoracic Oncology Division at the European Institute of Oncology (IEO), Milan, Italy Barbara Melosky, MD, FRCPC, University of British Columbia and British Columbia Cancer Agency, Vancouver, Canada Nir Peled, MD, PhD, Pulmonologist & Medical Oncologist, Thoracic Cancer Unit, Petach Tiqwa, Israel Robert Pirker, MD, Medical University of Vienna, Vienna, Austria Martin Reck, MD, Lungen Clinic Grosshansdorf, Grosshansdorf, Germany Matthias Scheffler, MD, Lung Cancer Group Cologne, Universitätsklinikum Köln, Cologne, Germany Riyaz Shah, PhD, FRCP, Kent Oncology Centre, Maidstone Hospital, Maidstone, UK Yu Shyr, PhD, Department of Biostatistics, Biomedical Informatics, Cancer Biology, and Health Policy, Nashville, TN, USA Masahiro Tsuboi, MD, Hospital East, National Cancer Center, Chiba, Japan Gustavo Werutsky, MD, Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil Yi-Long Wu, MD, FACS, Guangdong Lung Cancer Institute, Guangzhou, PR China Lecture Board for this issue: Maximilian Hochmair, MD; Luis M. Montuenga, PhD; Ross Soo, MB BS, PhD; Alexander Spira, MD, PhD Supported by Boehringer Ingelheim in the form of an unrestricted grant 2 1/2021 © Springer-Verlag memo special issue WCLC 2020 the same time, customization of adju- Preface vant chemotherapy based on genomic profiling did not contribute to survival Dear Colleagues, prolongation. In advanced lung cancer, targeted therapy is gaining ground as The 2020 World Conference of Lung various molecular aberrations are be- Cancer (WCLC) originally scheduled coming amenable to treatment, includ- for August 2020 in Singapore had to be ing the KRAS p.G12C mutation which is postponed to January 2021 due to the found in approximately 13 % of lung COVID-19 pandemic and was finally adenocarcinomas. Convincing findings own © author’s held as a worldwide virtual conference have been obtained for a first-in-class from 28th to 31st January. WCLC, which KRASG12C inhibitor. Furthermore, re- free treatment. Combinations with tar- is the leading gathering of interna- fined treatment of HER aberrations of- geted agents allow for tackling the tional scientists, researchers and fers new possibilities, and in EGFR-mu- disease from different directions and patient advocates in the field of lung tant lung cancer, innovative agents and might enhance the efficacy of immuno- cancer and thoracic malignancies, regimens have demonstrated antitumor therapy. Nevertheless, early detection continues to provide a forum to con- efficacy in difficult-to-treat settings in- of lung cancer undoubtedly provides nect, share knowledge and learn about cluding resistant disease. Among others, unique advantages, even though the the latest developments in the research antibody-drug conjugates represent a implementation of low-dose com- and treatment of these diseases. versatile new technology that certainly puted tomography screening still faces This publication summarizes con- meets the expectations regarding a 21st- obstacles in many countries. Biomark- tent reported at the conference in vari- century individualized approach. ers might help to improve the selection ous areas of clinical interest ranging Immunotherapy has become a main- of high-risk individuals who can be from early-stage disease to the meta- stay of lung cancer treatment in various expected to benefit from screening static setting. Targeted therapies have settings. Important analyses presented programs. succeeded in improving disease-free at WCLC 2020 related to findings ob- survival in patients diagnosed with tained with a range of combination regi- Ross A. Soo, MB BS, PhD, FRACP early-stage lung cancer who tended to mens not all of which proved successful, Department of Haematology-Oncology experience recurrence regardless of although checkpoint inhibition gener- National University Cancer Institute, postoperative chemotherapy use. At ally opens up the road to chemotherapy- Singapore Pushing the bounds in early-stage lung cancer ADAURA: role of adjuvant icant and clinically meaningful im- therapy use and outcomes observed in chemotherapy provement in disease-free survival ADAURA [10]. (DFS) with the adjuvant administration As expected, higher-stage disease Approximately 30 % of patients with of the third-generation EGFR tyrosine and younger age (< 70 years) were gen- non-small-cell lung cancer (NSCLC) kinase inhibitor (TKI) osimertinib (HR, erally associated with increased adju- present with resectable disease at diag- 0.20; p < 0.0001) in patients with com- vant chemotherapy use as compared to nosis [1-3]. Surgery with curative intent pletely resected stage IB-IIIA, EGFR- lower disease stage and older age, while is the recommended treatment here, mutated NSCLC [8, 9]. Osimertinib WHO performance status (0 or 1) did followed by adjuvant cisplatin-based (n = 339) was compared to placebo not affect the treatment decision. Over- chemotherapy in stage II/IIIA and select (n = 343) with and without concomitant all, chemotherapy use was in keeping cases of stage IB disease [4-6]. However, use of adjuvant chemotherapy. In both with observations from previous studies recurrence rates remain high across dis- treatment arms, 60 % of patients re- and clinical practice [11, 12]. DFS bene- ease stages, regardless of postoperative ceived chemotherapy for a median of 4 fits obtained with osimertinib vs. pla- chemotherapy use [7]. The randomized, cycles prior to randomization. At WCLC cebo did not depend on whether double-blind, phase III ADAURA study 2020, Wu et al. reported an exploratory chemotherapy had been administered has revealed a highly statistically signif- analysis relating to adjuvant chemo- or not. Patients after adjuvant chemo- memo © Springer-Verlag 1/2021 3 WCLC 2020 special issue TABLE 1 Disease-free survival in ADAURA according to disease stage and use of adjuvant chemotherapy Stage Study treatment Median DFS, months HR Median DFS, months HR With adjuvant chemotherapy Without adjuvant chemotherapy Overall Osimertinib Not reached 0.16 Not reached 0.23 Placebo 22.1 33.1 IB Osimertinib Not reached Not calculable Not reached 0.38 Placebo 48.2 Not reached II Osimertinib Not reached 0.15 Not reached 0.20 Placebo 29.4 22.1 IIIA Osimertinib 38.8 0.13
Load more

Recommended publications
  • The Predictive Values of Advanced Non-Small Cell Lung
    ORIGINAL RESEARCH published: 26 August 2021 doi: 10.3389/fonc.2021.646577 The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Edited by: Genetic Alterations Francois X. Claret, University of Texas MD Anderson † † Cancer Center, United States Jiarong Tan , Chengping Hu , Pengbo Deng*, Rongjun Wan, Liming Cao, Min Li, Reviewed by: Huaping Yang, Qihua Gu, Jian An and Juan Jiang Lin Liu, Department of Respiratory Medicine, Xiangya Hospital of Central South University, Changsha, China Nankai University, China Hui Guo, First Affiliated Hospital of Xi’an Introduction: Epidermal growth factor receptor (EGFR) 19del and L858R mutation are Jiaotong University, China “ ” Tony Y. Hu, known as common mutations in non-small cell lung cancer (NSCLC) and predict Tulane University, United States sensitivities to EGFR tyrosine kinase inhibitors (TKIs), whereas 20ins and T790M *Correspondence: mutations confer drug-resistance to EGFR-TKIs. The role of the remaining uncommon Pengbo Deng EGFR mutations remains elusive. [email protected] †These authors have contributed Methods: We retrospectively screened a group of NSCLC patients with uncommon equally to this work EGFR mutations other than 20ins and T790M. The mutation patterns, use of different generations of EGFR-TKIs, and concurrent genetic alterations were analyzed. Meanwhile, Specialty section: This article was submitted to a cohort of patients with single 19del or L858R were included for comparison. Cancer Molecular Targets Results: A total of 180/1,300 (13.8%) patients were identified. There were 102 patients and Therapeutics, a section of the journal with advanced or recurrent NSCLC that received first-line therapy of gefitinib/erlotinib/ Frontiers in Oncology icotinib and afatinib and were eligible for analysis.
    [Show full text]
  • Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
    Int. J. Mol. Sci. 2014, 15, 13768-13801; doi:10.3390/ijms150813768 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies Mohammad Hojjat-Farsangi Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm 17176, Sweden; E-Mail: [email protected]; Tel.: +46-517-74308; Fax: +46-517-75897 Received: 3 July 2014; in revised form: 31 July 2014 / Accepted: 5 August 2014 / Published: 8 August 2014 Abstract: Chemotherapeutic and cytotoxic drugs are widely used in the treatment of cancer. In spite of the improvements in the life quality of patients, their effectiveness is compromised by several disadvantages. This represents a demand for developing new effective strategies with focusing on tumor cells and minimum side effects. Targeted cancer therapies and personalized medicine have been defined as a new type of emerging treatments. Small molecule inhibitors (SMIs) are among the most effective drugs for targeted cancer therapy. The growing number of approved SMIs of receptor tyrosine kinases (RTKs) i.e., tyrosine kinase inhibitors (TKIs) in the clinical oncology imply the increasing attention and application of these therapeutic tools. Most of the current approved RTK–TKIs in preclinical and clinical settings are multi-targeted inhibitors with several side effects. Only a few specific/selective RTK–TKIs have been developed for the treatment of cancer patients. Specific/selective RTK–TKIs have shown less deleterious effects compared to multi-targeted inhibitors.
    [Show full text]
  • Efficacy and Influence Factors of Icotinib Hydrochloride in Treating Advanced Non-Small Cell Lung Cancer
    European Review for Medical and Pharmacological Sciences 2017; 21: 266-274 Efficacy and influence factors of icotinib hydrochloride in treating advanced non-small cell lung cancer X.-H. MA, T.-D. TIAN, H.-M. LIU, Q.-J. LI, Q.-L. GAO, L. LI, B. SHI Integrated TCM & Western Medicine Department, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China Abstract. – OBJECTIVE: To evaluate the effi- Introduction cacy and safety of icotinib hydrochloride in the treatment of patients with advanced non-small In the most parts of the world, the lung cancer cell lung cancer (NSCLC) and discuss the influ- ranks on the top list between global tumor occur- ence factors on efficacy. rence and mortality, which seriously threatens PATIENTS AND METHODS: 120 treatment-ex- the human health and life. Lung cancer mainly perienced patients confirmed by pathology or includes non-small cell lung cancer (NSCLC) cytology with stage III B-IV non-small cell lung cancer took icotinib hydrochloride and erlotinib and small cell lung cancer (SCLC), in which orally until the occurrence of disease progres- NSCLC accounts for 80% and has a five-year 1,2 sion or serious adverse reactions. Then, the effi- survival rate of only 12-15% . Due to the oc- cacy of icotinib hydrochloride and the related in- cult features of lung cancer at the early stages, fluence factors were analyzed. over 70% patients with lung cancer have missed RESULTS: In icotinib hydrochloride group, the the chance of surgery when they felt ill. More- response rate and the disease control rate were over, less than 1/3 NSCLC patients are early 30.00% and 65.00%, and the median progres- sion-free survival time was 179 days (95% CI: diagnosed and subjected to excision.
    [Show full text]
  • Targeted/Immunotherapy & Molecular Profiling – State-Of-The-Art in Cancer
    Targeted/Immunotherapy & Molecular Profiling – State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic 1 Outline • Role of Molecular Profiling in the management of brain metastases • Targeted/Immunotherapy in Management of brain metastases • Management of brain metastases in the coming 3–5 years 2 Epidemiology of brain metastases Primary tumor Relative prevalence of brain metastases* Colon: 5% Annual US incidence: >170K Ratio mets/primary: 10:1 All cancer patients: 15%–30% Melanoma: 9% Autopsy incidence: 10%–30% Mean age: 60 years Unknown primary: 11% Median survival: 4–6 months Other known primary: 13% Breast: 15% Lung: 48% *Incidence increasing with better systemic Rx and improved survival Courtesy: John Suh. Wen PY, et al. In: DeVita VT Jr, et al, eds. 3 Cancer: Principles & Practice of Oncology. 2001:2656-2670. Incidence of brain metastasis is increasing Incidence of brain metastasis is increasing1: • Improvements in imaging (e.g. MRI) • Clinical trial screening • Improvements in systemic cancer control (brain is a sanctuary site) • Rates of brain metastasis may be influenced by Brain metastases may be changing treatments underdiagnosed • Autopsy results reveal brain – 25% of lung cancer patients have brain metastasis at initial metastases that were not presentation diagnosed clinically2 • Clinical trial screening reveals – 80% of lung cancer patients patients with asymptomatic surviving >2 years will develop brain metastases1 brain metastases 1. Ba JL et al. Oncology 2015; 29: 250-257; 2. Ahluwalia MS, Winkler F. ASCO 2015: MRI, magnetic resonance imaging. http://meetinglibrary.asco.org/content/115000067-156.
    [Show full text]
  • Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi*
    Huang et al. J Hematol Oncol (2020) 13:143 https://doi.org/10.1186/s13045-020-00977-0 REVIEW Open Access Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi* Abstract Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then block the activation of downstream signaling pathways. Over the past 20 years, multiple robust and well-tolerated TKIs with single or multiple targets including EGFR, ALK, ROS1, HER2, NTRK, VEGFR, RET, MET, MEK, FGFR, PDGFR, and KIT have been developed, contributing to the realization of precision cancer medicine based on individual patient’s genetic alteration features. TKIs have dramatically improved patients’ survival and quality of life, and shifted treatment paradigm of various solid tumors. In this article, we summarized the developing history of TKIs for treatment of solid tumors, aiming to provide up-to-date evidence for clinical decision-making and insight for future studies. Keywords: Tyrosine kinase inhibitors, Solid tumors, Targeted therapy Introduction activation of tyrosine kinases due to mutations, translo- According to GLOBOCAN 2018, an estimated 18.1 cations, or amplifcations is implicated in tumorigenesis, million new cancer cases and 9.6 million cancer deaths progression, invasion, and metastasis of malignancies. occurred in 2018 worldwide [1]. Targeted agents are In addition, wild-type tyrosine kinases can also func- superior to traditional chemotherapeutic ones in selec- tion as critical nodes for pathway activation in cancer.
    [Show full text]
  • Lncrna APCDD1L-AS1 Induces Icotinib Resistance by Inhibition Of
    Wu et al. Biomarker Research (2021) 9:9 https://doi.org/10.1186/s40364-021-00262-3 RESEARCH Open Access LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/ miR-324-3p-SIRT5 axis in lung adenocarcinoma Jie Wu1,2†, Chunlei Zheng3,4,5†, Yizhe Wang1, Zichang Yang3,4,5,CeLi3,4,5, Wanxia Fang3,4,5, Yue Jin3,4,5, Kezuo Hou3,4,5, Yang Cheng1, Jianfei Qi6, Xiujuan Qu3,4,5, Yunpeng Liu3,4,5, Xiaofang Che3,4,5* and Xuejun Hu1* Abstract Background: Epidermal growth factor receptor-tyrosinase kinase inhibitor (EGFR-TKI) resistance is the major obstacle in the treatment of lung adenocarcinoma (LUAD) patients harboring EGFR-sensitive mutations. However, the long non-coding RNAs (lncRNAs) related to EGFR-TKIs resistance and their functional mechanisms are still largely unknown. This study aimed to investigate the role and regulatory mechanism of lncRNA APCDD1L-AS1 in icotinib resistance of lung cancer. Methods: Molecular approaches including qRT-PCR, MTT assay, colony formation, RNA interference and cell transfection, RNA immunoprecipitation (RIP), dual luciferase reporter assay, RNA fluorescence in situ hybridization, TUNEL assay, flow cytometry, immunoblotting, xenograft model and transcriptome sequencing were used to investigate the mechanism of APCDD1L-AS1 in icotinib resistance. Results: A novel lncRNA, APCDD1L-AS1 was identified as the most significantly upregulated lncRNA in icotinib- resistant LUAD cells by the transcriptome sequencing and differential lncRNA expression analysis. We found that APCDD1L-AS1 not only promoted icotinib resistance, but also upregulated the protein expression level of EGFR. Mechanistically, APCDD1L-AS1 promoted icotinib resistance and EGFR upregulation by sponging with miR-1322/ miR-1972/miR-324-3p to remove the transcription inhibition of SIRT5.
    [Show full text]
  • Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
    cancers Review Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy 1,2, 3,4 1 2 3, Charles Pottier * , Margaux Fresnais , Marie Gilon , Guy Jérusalem ,Rémi Longuespée y 1, and Nor Eddine Sounni y 1 Laboratory of Tumor and Development Biology, GIGA-Cancer and GIGA-I3, GIGA-Research, University Hospital of Liège, 4000 Liège, Belgium; [email protected] (M.G.); [email protected] (N.E.S.) 2 Department of Medical Oncology, University Hospital of Liège, 4000 Liège, Belgium; [email protected] 3 Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital of Heidelberg, 69120 Heidelberg, Germany; [email protected] (M.F.); [email protected] (R.L.) 4 German Cancer Consortium (DKTK)-German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany * Correspondence: [email protected] Equivalent contribution. y Received: 17 January 2020; Accepted: 16 March 2020; Published: 20 March 2020 Abstract: Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer cell growth and metastasis. During the last two decades, several molecules targeting RTKs were used in oncology as a first or second line therapy in different types of cancer. However, their effectiveness is limited by the appearance of resistance or adverse effects. In this review, we summarize the main features of RTKs and their inhibitors (RTKIs), their current use in oncology, and mechanisms of resistance. We also describe the technological advances of artificial intelligence, chemoproteomics, and microfluidics in elaborating powerful strategies that could be used in providing more efficient and selective small molecules inhibitors of RTKs.
    [Show full text]
  • Effects of Icotinib, a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer
    2066 ONCOLOGY REPORTS 27: 2066-2072, 2012 Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer GUANGDIE YANG*, YINAN YAO, JIANYA ZHOU and QIONG ZHAO* Department of Respiratory Disease, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou 310003, Zhejiang, P.R. China Received January 11, 2012; Accepted February 13, 2012 DOI: 10.3892/or.2012.1741 Abstract. Epidermal growth factor receptor (EGFR) is one treated with surgery, radiation and chemotherapy (2). The use of the most promising targets for non-small cell lung cancer of targeted therapies is increasing as the survival advantage for (NSCLC). Our study demonstrated the antitumor effects of adjuvant chemotherapy is less than 5% with increased toxicity icotinib hydrochloride, a highly selective epidermal growth (3,4). Although chemotherapy has been the standard of care for factor receptor tyrosine kinase inhibitor (EGFR TKI), in two NSCLC patients, current clinical efforts are directed at targeted EGFR-mutated lung cancer cell lines compared to A549, a cell agents to improve outcome and reduce toxicity (5). The most line without EGFR mutations. We incubated PC-9 and HCC827 common targeted agents that are being used in the treatment human lung cancer cell lines both with (E746-A750) mutations of NSLC include those that target key components in cancer with various concentrations of icotinib and gefitinib for 48 h. cell signaling, such as the vascular endothelial growth factor Cell proliferation and migration were determined using a real- receptor (VEGFR), platelet-derived growth factor receptor time cell invasion and migration assay and cytotoxicity assay.
    [Show full text]
  • Hand-Foot Syndrome in a Patient with Metastatic Lung Adenocarcinoma Induced by High-Dose Icotinib: a Case Report and Review of the Literature
    ONCOLOGY LETTERS 4: 1341-1343, 2012 Hand-foot syndrome in a patient with metastatic lung adenocarcinoma induced by high-dose icotinib: A case report and review of the literature YULONG ZHENG, WEIJIA FANG and NONG XU Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P.R. China Received April 18, 2012; Accepted July 27, 2012 DOI: 10.3892/ol.2012.904 Abstract. Icotinib is a new oral epidermal growth factor cytarabine, docetaxel and capecitabine (5), as well as certain tyrosine kinase inhibitor (EGFR-TKI). The most frequent oral targeted therapies such as sunitinib and sorafenib (6). side-effects of icotinib include rash and diarrhea. Hand-foot HFS induced by EGFR-TKI is uncommon and has been only syndrome (HFS) induced by EGFR-TKI is rare. The present sporadically reported in the literature (7-9). We report a case study describes, for the first time, HFS induced by high‑dose of HFS caused by high-dose icotinib, which, to the best of our icotinib in a 65-year old female with metastatic lung adeno- knowledge, has not been previously described. carcinoma. The patient developed HFS during the first week of icotinib treatment with characteristic clinical presentation. Case report HFS regressed after icotinib dose-reduction was initiated. HFS may occur with icotinib, especially when administered A 65-year old female (non-smoker) with metastatic lung in high doses. adenocarcinoma received one cycle of intravenous chemo- therapy with pemetrexed (500 mg/m2, on day 1) plus cisplatin Introduction (25 mg/m2, on days 1-3). The patient experienced serious vomiting (NCI-CTC 3.0, grade 3) and refused to continue.
    [Show full text]
  • A Marked Response to Icotinib in a Patient with Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation: a Case Report
    ONCOLOGY LETTERS 10: 1575-1578, 2015 A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation: A case report YUEHONG WANG, YI HONG SHEN, SHANNI MA and JIANYING ZHOU Department of Respiratory Disease, The First Affiliated Hospital of the College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China Received September 7, 2014; Accepted May 29, 2015 DOI: 10.3892/ol.2015.3405 Abstract. The present study reports the case of an 84-year-old evidence has indicated that LCNEC shares numerous morpho- male with primary pulmonary large cell neuroendocrine logical, immunohistochemical and molecular characteristics carcinoma (LCNEC) harboring an epidermal growth factor with small cell lung cancer (SCLC), as well as treatment receptor (EGFR) gene mutation that exhibited a long-lasting strategies and a poor prognosis (1). The optimal treatment response to the EGFR-tyrosine kinase inhibitor (EGFR-TKI) regime for patients with LCNEC has yet to be established. icotinib. The patient had an extensive smoking history, a poor Recently, the use of epidermal growth factor receptor-tyrosine performance status, and presented with an irregular mass in the kinase inhibitors (EGFR-TKIs) has been demonstrated to be middle lobe of the right lung on computed tomography (CT) an effective therapeutic strategy for patients with non-SCLC and an enlarged left supraclavicular lymph node on physical (NSCLC), particularly for those with EGFR mutations (2,3). examination. Right middle lobe bronchial brushing during However, EGFR mutations typically occur in patients with fiberoptic bronchoscopyidentified poorly‑differentiated cancer adenocarcinoma and investigations of EGFR mutations in cells.
    [Show full text]
  • And Second-Generation Tkis—There Is Still Place for Them in EGFR-Mutant NSCLC Patients
    47 Review Article EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients Niki Karachaliou1,2, Manuel Fernandez-Bruno1, Jillian Wilhelmina Paulina Bracht2, Rafael Rosell2,3,4,5 1QuironSalud Group, Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain; 2Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain; 3Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain; 4Institute of Oncology Rosell (IOR), Quiron-Dexeus University Institute, Barcelona, Spain; 5Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain Contributions: (I) Conception and design: N Karachaliou, R Rosell; (II) Administrative support: All authors; (III) Provision of study materials or patients: N Karachaliou, M Fernandez-Bruno; (IV) Collection and assembly of data: N Karachaliou, M Fernandez-Bruno, JW Bracht; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Rafael Rosell. Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain; Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain. Email: [email protected]; Niki Karachaliou. QuironSalud Group, Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain. Email: [email protected]. Abstract: Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard chemotherapy to personalized, targeted therapy. First-, second- and third-generation EGFR tyrosine kinase inhibitors (TKIs) are now available for the treatment of EGFR-mutant NSCLC patients. This review will focus on the clinical development of first- and second-generation EGFR TKIs.
    [Show full text]
  • Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
    pharmaceuticals Review Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Kyu Sic You 1,2,† , Yong Weon Yi 3,† , Jeonghee Cho 3 , Jeong-Soo Park 1,* and Yeon-Sun Seong 1,2,3,* 1 Department of Biochemistry, College of Medicine, Dankook University, Cheonan 31116, Chungcheongnam-do, Korea; [email protected] 2 Graduate School of Convergence Medical Science, Dankook University, Cheonan 3116, Chungcheongnam-do, Korea 3 Department of Nanobiomedical Science, Dankook University, Cheonan 31116, Chungcheongnam-do, Korea; [email protected] (Y.W.Y.); [email protected] (J.C.) * Correspondence: [email protected] (J.-S.P.); [email protected] (Y.-S.S.); Tel.: +82-41-550-3876 (J.-S.P.); +82-41-550-3875 (Y.-S.S.) † These authors contributed equally to this work. Abstract: Triple-negative breast cancer (TNBC) is a subset of breast cancer with aggressive charac- teristics and few therapeutic options. The lack of an appropriate therapeutic target is a challenging issue in treating TNBC. Although a high level expression of epidermal growth factor receptor (EGFR) has been associated with a poor prognosis among patients with TNBC, targeted anti-EGFR therapies have demonstrated limited efficacy for TNBC treatment in both clinical and preclinical settings. However, with the advantage of a number of clinically approved EGFR inhibitors (EGFRis), combi- nation strategies have been explored as a promising approach to overcome the intrinsic resistance of TNBC to EGFRis. In this review, we analyzed the literature on the combination of EGFRis with Citation: You, K.S.; Yi, Y.W.; Cho, J.; other molecularly targeted therapeutics or conventional chemotherapeutics to understand the current Park, J.-S.; Seong, Y.-S.
    [Show full text]